ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

Core Insights - Amplia Therapeutics Limited presented interim data from the ACCENT trial for metastatic pancreatic cancer at the ASCO GI symposium, showcasing the efficacy of narmafotinib in combination with standard chemotherapy [1][3] Group 1: Clinical Trial Data - The ACCENT trial is assessing narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for advanced pancreatic cancer patients [1][5] - Updated progression-free survival (PFS) for the narmafotinib combination is reported at 7.7 months, compared to 5.5 months for gemcitabine and Abraxane alone [6] - The overall response rate (ORR) for the narmafotinib combination is 35%, increasing to 42% when including unconfirmed responses [6][7] - The trial has achieved a confirmed response rate of 35%, superior to the 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone [7] Group 2: Company Overview - Amplia Therapeutics is focused on developing a pipeline of FAK inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer [4][5] - Narmafotinib (AMP945) is highlighted as a best-in-class FAK inhibitor, showing promising preclinical data and currently undergoing clinical trials [5][6] - The company is positioned among leading biotechnology firms, emphasizing its progress in developing narmafotinib for pancreatic cancer [3]